Infigratinib in Recurrent High-Grade Glioma Patients

A Phase 0 Study of Infigratinib in Recurrent High-Grade Glioma Participants Scheduled for Resection to Evaluate Central Nervous System (CNS) Penetration With PK Triggered Expansion Cohort

This trial is an open-label, multicenter, Phase 0 trial that will enroll up to 20 participants with recurrent high-grade glioma with FGFR1 K656E or FGFR3 K650E mutation or FGFR3-TACC3 translocation which are scheduled for resection. In the lead-in cohort, a total of 20 participants will be enrolled into the proposed phase 0 clinical trial. Participants will be administered infigratinib prior to surgical resection of their tumor.

Study Overview

• Status: Terminated
• Conditions: Glioma; Glioblastoma; GBM
• Intervention / Treatment: Drug: Infigratinib

• Study Type: Interventional
• Enrollment (Actual): 7
• Phase: Early Phase 1

Contacts and Locations

Study Locations

• United States
  • Arizona
    • Chandler, Arizona, United States, 85224
      • Chandler Regional Medical Center
    • Phoenix, Arizona, United States, 85013
      • St. Joseph's Hospital and Medical Center
    • Scottsdale, Arizona, United States, 85251
      • HonorHealth Scottsdale Osborn Medical Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Prior resection of histologically diagnosed high-grade gliomas (III and IV) defined as participants who have progressed on or following standard (Stupp regimen) therapy, which included maximal surgical resection, temozolomide, and fractionated radiotherapy.
2. Recurrence must be confirmed by diagnostic biopsy with local pathology review or contrast-enhanced MRI.
3. Have measurable disease preoperatively, defined as at least 1 contrast-enhancing lesion, with 2 perpendicular measurements of at least 1 cm, as per RANO criteria.
4. Sufficient archival tissue available to confirm eligibility.
5. Archival tissue must demonstrate: FGFR1 K656E or FGFR3 K650E mutation or FGFR3-TACC3 translocation from NGS sequencing or IHC and RT-PCR.
6. Ability to understand and the willingness to sign a written informed consent document (personally or by the legally authorized representative, if applicable).
7. Has voluntarily agreed to participate by giving written informed consent (personally or via legally authorized representative(s), and assent if applicable). Written informed consent for the protocol must be obtained prior to any screening procedures. If consent cannot be expressed in writing, it must be formally documented and witnessed, ideally via an independent trusted witness.
8. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests and other procedures.
9. Age ≥18 at time of consent
10. Have a performance status (PS) of ≤2 on the Eastern Cooperative Oncology (Group (ECOG) scale (Oken et al. 1982)
11. Ability to swallow oral medications.

12. Has adequate bone marrow and organ function as defined by the following laboratory values (as assessed by the local laboratory for eligibility):

    1. Adequate bone marrow function:

       • absolute neutrophil count ≥1,000/mcL
       • Platelets (at time of surgery) ≥100,000/mcL
       • hemoglobin ≥8.0 g/dL Participants may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the investigator.

    2. Adequate hepatic and renal function:

       • total bilirubin ≤1.5 X ULN Participants with Gilbert's syndrome with a total bilirubin ≤2.0 times ULN and direct bilirubin within normal limits are permitted.
       • AST(SGOT) ≤3 X institutional ULN
       • ALT(SGPT) ≤3 X institutional ULN
       • Calculated or measured creatinine clearance ≥45 mL/min

    3. Other Lab Values:

       • Amylase or lipase ≤2 X institutional ULN
       • calcium or phosphorus, or calcium-phosphorus product <55 mg2/dL2
    1. Inorganic phosphorus within normal limits
    2. Total corrected serum calcium within normal limits
13. Confirmed negative serum pregnancy test (β-hCG) before starting study treatment or participant has had a hysterectomy.
14. For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional 3 months after the end of treatment administration.
15. For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner and for an additional 1 month after the end of treatment administration. A condom is required to be used also by vasectomized men as well as during intercourse with a male partner to prevent delivery of the drug via seminal fluid.
16. Agreement to adhere to Lifestyle Considerations throughout study duration.
17. Participants who received chemotherapy must have recovered (Common Terminology Criteria for Adverse Events [CTCAE] Grade ≤1) from the acute effects of chemotherapy except for residual alopecia or Grade 2 peripheral neuropathy prior to Day 1. A washout period of at least 21 days is required between last chemotherapy dose and Day 1 (provided the patient did not receive radiotherapy).
18. Participants who received radiotherapy must have completed and fully recovered from the acute effects of radiotherapy. A washout period of at least 14 days is required between end of radiotherapy and Day 1.

Exclusion Criteria:

1. Have a history of liver transplant.
2. Have impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral infigratinib (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection).
3. Known active systemic bacterial infection (requiring intravenous [IV] antibiotics at time of initiating study treatment), fungal infection, or detectable viral infection (such as known human immunodeficiency virus positivity or with known active hepatitis B or C [for example, hepatitis B surface antigen positive]. Screening is not required for enrollment.
4. Have a history and/or current evidence of extensive tissue calcification including, but not limited to, the soft tissue, kidneys, intestine, myocardium, vascular system, and lung with the exception of calcified lymph nodes, minor pulmonary parenchymal calcifications, and asymptomatic coronary calcification.
5. Have current evidence of corneal or retinal disorder/keratopathy including, but not limited to, bullous/band keratopathy, inflammation or ulceration, keratoconjunctivitis confirmed by ophthalmic examination. Subjects with asymptomatic ophthalmic conditions assessed by the investigator to pose minimal risk for study participation may be enrolled in the study.
6. Have current evidence of endocrine alterations of calcium/phosphate homeostasis, e.g., parathyroid disorders, history of parathyroidectomy, tumor lysis, tumoral calcinosis etc.
7. Have had a recent (≤3 months prior to first dose of study drug) transient ischemic attack or stroke.
8. CTCAE (v5.0) Grade ≥2 hearing loss.
9. CTCAE (v5.0) Grade ≥2 neuropathy.

10. Have clinically significant cardiac disease including any of the following:

    1. Known congestive heart failure requiring treatment (New York Heart Association Grade ≥2), LVEF <50% or local lower limit of normal as determined by MUGA scan or echocardiogram (ECHO), or uncontrolled hypertension (refer to the European Society of Cardiology and European Society of Hypertension guidelines [Williams et al 2018]).
    2. Presence of Common Terminology Criteria for Adverse Events (CTCAE) v5.0 Grade ≥2 ventricular arrhythmias, atrial fibrillation, bradycardia, or conduction abnormality.
    3. Unstable angina pectoris or acute myocardial infarction ≤3 months prior to first dose of study drug.
    4. QTcF >470 msec (males and females). Note: If the QTcF is >470 msec in the first ECG, a total of 3 ECGs separated by at least 5 minutes should be performed. If the average of these 3 consecutive results for QTcF is ≤470 msec, the participant meets eligibility in this regard.
    5. Known history of congenital long QT syndrome.
11. Has serious and/or uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study (for example, interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, severe renal impairment [e.g. estimated creatinine clearance <30ml/min], history of major surgical resection involving the stomach or small bowel, or preexisting Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea).
12. Prior therapy with any mitogen-activated protein kinase (MEK) or FGFR inhibitor. Prior therapy is defined as a therapeutic dosing, as determined by the Investigator.
13. Are currently receiving or are planning to receive during participation in this study, treatment with agents that are known strong inducers or inhibitors of CYP3A4 and medications which increase serum phosphorus and/or calcium concentration. Participants are not permitted to receive enzyme-inducing anti-epileptic drugs, including carbamazepine, phenytoin, phenobarbital, and primidone.
14. Current use of coumarin-derived anticoagulant for treatment, prophylaxis or otherwise. Therapy with heparin, low molecular weight heparin (LMWH) or fondaparinux is allowed.
15. Have any known hypersensitivity to gemcitabine, cisplatin, calcium-lowering agents, infigratinib, or their excipients.
16. Treatment with another investigational drug or other intervention within 30 days prior to enrollment or within 5 half-lives of the investigational product, whichever is longer.
17. Have consumed grapefruit, grapefruit juice, grapefruit hybrids, pomegranates, star fruits, pomelos, Seville oranges or products containing juice of these fruits within 7 days prior to first dose of study drug.
18. Have used medications known to prolong the QT interval and/or are associated with a risk of Torsades de Pointes (TdP) 7 days prior to first dose of study drug.
19. Have used amiodarone within 90 days prior to first dose of study drug.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Arm 1; Phase 0: 125 mg of infigratinib administered orally for 7 days prior to surgical resection. Expansion Cohort: 125 mg of infigratinib administered orally for 21 days of a 28-day treatment cycles.	Drug: Infigratinib; The Phase 0 study will include treatment of recurrent high-grade glioma participants with 125 mg of infigratinib 7 days prior to surgical resection. Participants with tumors demonstrating PK-response will continue treatment with the same dose continuously for 21 days in 28-day cycles after surgery.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Total Concentration of Infigratinib in Enhancing and Non-Enhancing Tumor Tissue	Phase 0: Total infigratinib concentration in Gd enhancing and Gd non-enhancing tumor tissue collected intraoperatively, approximately 8 hours after study drug administration, will be determined by a validated liquid chromatography-mass spectrometry (LC-MS) method.	Intraoperative
Unbound Concentration of Infigratinib in Enhancing and Non-Enhancing Tumor Tissue	Phase 0: Unbound infigratinib concentration in Gd enhancing and Gd non-enhancing tumor tissue collected intraoperatively, approximately 8 hours after study drug administration, will be determined by a validated liquid chromatography-mass spectrometry (LC-MS) method.	Intraoperative
Total Concentration of Infigratinib in Plasma	Phase 0: Total infigratinib concentration in blood plasma collected intraoperatively, approximately 8 hours after study drug administration, will be determined by a validated liquid chromatography-mass spectrometry (LC-MS) method.	Intraoperative
Unbound Concentration of Infigratinib in Plasma	Phase 0: Unbound infigratinib concentration in blood plasma collected intraoperatively, approximately 8 hours after study drug administration, will be determined by a validated liquid chromatography-mass spectrometry (LC-MS) method.	Intraoperative
Total Concentration of Infigratinib in Cerebrospinal Fluid (CSF)	Phase 0: Total infigratinib concentration in cerebrospinal fluid (CSF) collected intraoperatively, approximately 8 hours after study drug administration, will be determined by a validated liquid chromatography-mass spectrometry (LC-MS) method.	Intraoperative
Unbound Concentration of Infigratinib in Cerebrospinal Fluid (CSF)	Phase 0: Unbound infigratinib concentration in cerebrospinal fluid (CSF) collected intraoperatively, approximately 8 hours after study drug administration, will be determined by a validated liquid chromatography-mass spectrometry (LC-MS) method.	Intraoperative
6-month Progression-Free Survival (PFS6) in Expansion Phase Participants	Proportion of participants who remain alive without disease progression at 6 months	From the date of Phase 0 surgery until the first documentation of disease progression or death due to any cause, assessed up to 6 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Mean % Change of pERK+ Cells in Resected Post-Treatment Recurrent HGG Tissue vs Baseline Tissue	Phase 0: The mean percentage change of pERK positive cells in resected post-treatment recurrent high-grade glioma tumor tissue compared to baseline (archival primary high-grade glioma tumor tissue collected at screening) will be quantified using immunohistochemistry.	Baseline, Intraoperatively
Mean % Change of MIB-1+ Cells in Resected Post-Treatment Recurrent HGG Tissue vs Baseline Tissue	Phase 0: The mean percentage change of MIB-1 positive cells in resected post-treatment recurrent high-grade glioma tumor tissue compared to baseline (archival primary high-grade glioma tumor tissue collected at screening) will be quantified using immunohistochemistry.	Baseline, Intraoperatively
Mean % Change of ClCas3+ Cells in Resected Post-Treatment Recurrent HGG Tissue vs Baseline Tissue	Phase 0: The mean percentage change of ClCase3 positive cells in resected post-treatment recurrent high-grade glioma tumor tissue compared to baseline (archival primary high-grade glioma tumor tissue collected at screening) will be quantified using immunohistochemistry.	Baseline, Intraoperatively
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Assessed by CTCAE v5.0	Expansion Phase: An AE that began after the start of study medication treatment; or if the event was continuous from baseline and was serious, study medication-related, or resulted in death, discontinuation, or interruption or reduction of trial therapy.	From date of first dose until 7 days after last dose, assessed over 2 years 6 months
Number of Participants With Treatment-Related Adverse Events (TRAEs) Assessed by CTCAE v5.0	Expansion Phase: TRAEs are those deemed definitely, probably, and potentially related to the study drug.	From date of first dose until 7 days after last dose, assessed over 2 years 6 months
Number of Participants With Serious Adverse Events	Expansion Phase: AE severity as defined according to CTCAE v5.0.	From date of first dose until 30 days after last dose, assessed over 2 years 6 months

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Total Infigratinib Peak Plasma Concentration (Cmax)	Phase 0: Total infigratinib peak plasma concentration (Cmax) in blood plasma will be determined by a validated liquid chromatography-mass spectrometry (LC-MS) method.	Day of surgery at pre-dose and 0.5, 1, 2, 4, 6, 8, and 24 hours post-dose
Unbound Infigratinib Peak Plasma Concentration (Cmax)	Phase 0: Unbound infigratinib peak plasma concentration (Cmax) in blood plasma will be determined by a validated liquid chromatography-mass spectrometry (LC-MS) method.	Day of surgery at pre-dose and 0.5, 1, 2, 4, 6, 8, and 24 hours post-dose
Total Infigratinib Time to Peak Plasma Concentration (Tmax)	Phase 0: Total infigratinib time to peak plasma concentration (Tmax) in blood plasma will be determined by a validated liquid chromatography-mass spectrometry (LC-MS) method.	Day of surgery at pre-dose and 0.5, 1, 2, 4, 6, 8, and 24 hours post-dose
Unbound Infigratinib Time to Peak Plasma Concentration (Tmax)	Phase 0: Unbound infigratinib time to peak plasma concentration (Tmax) in blood plasma will be determined by a validated liquid chromatography-mass spectrometry (LC-MS) method.	Day of surgery at pre-dose and 0.5, 1, 2, 4, 6, 8, and 24 hours post-dose
Total Infigratinib Concentration Half-Life (T1/2)	Phase 0: Total infigratinib concentration half-life (T1/2) in blood plasma will be determined by a validated liquid chromatography-mass spectrometry (LC-MS) method.	Day of surgery at pre-dose and 0.5, 1, 2, 4, 6, 8, and 24 hours post-dose
Unbound Infigratinib Concentration Half-Life (T1/2)	Phase 0: Unbound infigratinib concentration half-life (T1/2) in blood plasma will be determined by a validated liquid chromatography-mass spectrometry (LC-MS) method.	Day of surgery at pre-dose and 0.5, 1, 2, 4, 6, 8, and 24 hours post-dose
Total Infigratinib Area Under the Plasma Concentration Versus Time Curve (AUC)	Phase 0: Total infigratinib area under the plasma concentration versus time curve (AUC) in blood plasma will be determined by a validated liquid chromatography-mass spectrometry (LC-MS) method.	Day of surgery at pre-dose and 0.5, 1, 2, 4, 6, 8, and 24 hours post-dose
Unbound Infigratinib Area Under the Plasma Concentration Versus Time Curve (AUC)	Phase 0: Unbound infigratinib area under the plasma concentration versus time curve (AUC) in blood plasma will be determined by a validated liquid chromatography-mass spectrometry (LC-MS) method.	Day of surgery at pre-dose and 0.5, 1, 2, 4, 6, 8, and 24 hours post-dose
Median Overall Survival (OS)	Expansion Phase: The number of days from the date of Phase 0 surgery until the date of death due to any cause.	From the date of Phase 0 surgery until the date of death due to any cause, assessed over 2 years 6 months

Collaborators and Investigators

• Sponsor: Nader Sanai
• Collaborators: Barrow Neurological Institute; Ivy Brain Tumor Center; QED Therapeutics, Inc., a Bridgebio company

Publications and helpful links

Helpful Links

• Ivy Brain Tumor Center Website

Study record dates

Study Major Dates

• Study Start (Actual): July 21, 2020
• Primary Completion (Actual): January 31, 2023
• Study Completion (Actual): February 19, 2024

Study Registration Dates

• First Submitted: May 27, 2020
• First Submitted That Met QC Criteria: June 5, 2020
• First Posted (Actual): June 11, 2020

Study Record Updates

• Last Update Posted (Estimated): October 24, 2025
• Last Update Submitted That Met QC Criteria: September 29, 2025
• Last Verified: September 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms; Neoplasms by Histologic Type; Neoplasms, Glandular and Epithelial; Astrocytoma; Neoplasms, Neuroepithelial; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms, Nerve Tissue; Glioblastoma; Glioma; Antineoplastic Agents; infigratinib
• Other Study ID Numbers: 2020-08; 20-500-092-34-38 (Other Identifier: SJHMC)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No